These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

405 related articles for article (PubMed ID: 27122198)

  • 1. Investigational therapies for renal disease-induced anemia.
    Schmid H; Jelkmann W
    Expert Opin Investig Drugs; 2016 Aug; 25(8):901-16. PubMed ID: 27122198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigational hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHI) for the treatment of anemia associated with chronic kidney disease.
    Del Vecchio L; Locatelli F
    Expert Opin Investig Drugs; 2018 Jul; 27(7):613-621. PubMed ID: 29975110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Will there still be a role for the originator erythropoiesis-simulating agents after the biosimilars and the hypoxia-inducible factor stabilizers approval?
    Locatelli F; Del Vecchio L
    Curr Opin Nephrol Hypertens; 2018 Sep; 27(5):339-344. PubMed ID: 29846220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypoxia-inducible factor prolyl hydroxylase inhibitors: a paradigm shift for treatment of anemia in chronic kidney disease?
    Souza E; Cho KH; Harris ST; Flindt NR; Watt RK; Pai AB
    Expert Opin Investig Drugs; 2020 Aug; 29(8):831-844. PubMed ID: 32476498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging drugs for the treatment of kidney disease-induced anemia.
    Malyszko J; Malyszko JS
    Expert Opin Emerg Drugs; 2016 Sep; 21(3):315-30. PubMed ID: 27537859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current and future chemical therapies for treating anaemia in chronic kidney disease.
    Locatelli F; Del Vecchio L; Luise MC
    Expert Opin Pharmacother; 2017 Jun; 18(8):781-788. PubMed ID: 28443351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New Treatment Approaches for the Anemia of CKD.
    Bonomini M; Del Vecchio L; Sirolli V; Locatelli F
    Am J Kidney Dis; 2016 Jan; 67(1):133-42. PubMed ID: 26372086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peginesatide for the treatment of renal disease-induced anemia.
    Schmid H
    Expert Opin Pharmacother; 2013 May; 14(7):937-48. PubMed ID: 23506424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experimental and investigational therapies for chemotherapy-induced anemia.
    Testa U; Castelli G; Elvira P
    Expert Opin Investig Drugs; 2015; 24(11):1433-45. PubMed ID: 26359222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitors in anaemia of chronic kidney disease: A meta-analysis including 13,146 patients.
    Chen H; Cheng Q; Wang J; Zhao X; Zhu S
    J Clin Pharm Ther; 2021 Aug; 46(4):999-1009. PubMed ID: 33615523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypoxia-inducible factor-prolyl hydroxylase inhibitors for renal anemia in chronic kidney disease: Advantages and disadvantages.
    Mima A
    Eur J Pharmacol; 2021 Dec; 912():174583. PubMed ID: 34678238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
    Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
    Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anemia in chronic kidney disease.
    Atkinson MA; Warady BA
    Pediatr Nephrol; 2018 Feb; 33(2):227-238. PubMed ID: 28412770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An overview on safety issues related to erythropoiesis-stimulating agents for the treatment of anaemia in patients with chronic kidney disease.
    Del Vecchio L; Locatelli F
    Expert Opin Drug Saf; 2016 Aug; 15(8):1021-30. PubMed ID: 27149639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting EPO and EPO receptor pathways in anemia and dysregulated erythropoiesis.
    Rainville N; Jachimowicz E; Wojchowski DM
    Expert Opin Ther Targets; 2016; 20(3):287-301. PubMed ID: 26419263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Managing Anemia across the Stages of Kidney Disease in Those Hyporesponsive to Erythropoiesis-Stimulating Agents.
    Weir MR
    Am J Nephrol; 2021; 52(6):450-466. PubMed ID: 34280923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Roxadustat in the treatment of anaemia in chronic kidney disease.
    Del Vecchio L; Locatelli F
    Expert Opin Investig Drugs; 2018 Jan; 27(1):125-133. PubMed ID: 29254377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Iron Metabolism in Chronic Kidney Disease Patients.
    Honda H; Hosaka N; Ganz T; Shibata T
    Contrib Nephrol; 2019; 198():103-111. PubMed ID: 30991401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel Masters of Erythropoiesis: Hypoxia Inducible Factors and Recent Advances in Anemia of Renal Disease.
    Solak Y; Cetiner M; Siriopol D; Tarim K; Afsar B; Covic A; Kanbay M
    Blood Purif; 2016; 42(2):160-7. PubMed ID: 27318465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging drugs for treatment of anemia of chronic kidney disease.
    Magwood JS; Lebby A; Chen B; Kessler S; Norris L; Bennett CL
    Expert Opin Emerg Drugs; 2013 Dec; 18(4):421-9. PubMed ID: 24033253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.